Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors
Thomas T. Joseph, Weiming Bu, Wen‐Zhen Lin, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 9, pp. 1487-1497
Open Access | Times Cited: 20

Showing 20 citing articles:

Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
The endogenous opioid system in the medial prefrontal cortex mediates ketamine’s antidepressant-like actions
Cheng Jiang, Ralph Dileone, Christopher Pittenger, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 10, pp. 4144-4156
Open Access | Times Cited: 31
A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?
Simone Pardossi, Andrea Fagiolini, Simona Scheggi, et al.
Children (2024) Vol. 11, Iss. 7, pp. 801-801
Open Access | Times Cited: 5
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Ivone Gomes, Achla Gupta, Elyssa B. Margolis, et al.
Molecular Pharmacology (2024) Vol. 106, Iss. 5, pp. 240-252
Closed Access | Times Cited: 5
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
Hildegard A. Wulf, Caroline A. Browne, Carlos A. Zarate, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2309-2316
Closed Access | Times Cited: 19
The ketamine metabolite (2R,6R)‐hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer's disease
Felipe C. Ribeiro, Danielle Cozachenco, Elentina K. Argyrousi, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5398-5410
Open Access | Times Cited: 4
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Alejandra Pulido-Saavedra, Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
(2R,6R)‐hydroxynorketamine prevents opioid abstinence‐related negative affect and stress‐induced reinstatement in mice
Andria Michael, Anna Onisiforou, Polymnia Georgiou, et al.
British Journal of Pharmacology (2025)
Open Access
Alchemical Free Energy Calculations on Membrane-Associated Proteins
Michail Papadourakis, Hryhory Sinenka, Pierre Matricon, et al.
Journal of Chemical Theory and Computation (2023) Vol. 19, Iss. 21, pp. 7437-7458
Open Access | Times Cited: 10
Endogenous opiates and behavior: 2021
Richard J. Bodnar
Peptides (2023) Vol. 164, pp. 171004-171004
Closed Access | Times Cited: 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen Wen, Wenjing Zhao, Xing Xia, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 242, pp. 173773-173773
Closed Access | Times Cited: 3
Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine
Miroslav Adžić, Iva Lukić, Miloš Mitić, et al.
Life Sciences (2023) Vol. 326, pp. 121803-121803
Closed Access | Times Cited: 8
New investigational agents for the treatment of major depressive disorder
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 1053-1066
Closed Access | Times Cited: 13
The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement
Caryssa R. Drinkuth, Michael J. Lehane, Gregory C. Sartor
Drug and Alcohol Dependence (2023) Vol. 253, pp. 110987-110987
Open Access | Times Cited: 7
Contribution of the Opioid System to the Antidepressant Effects of Fluoxetine
Elena Carazo-Arias, Phi T. Nguyen, Marley D. Kass, et al.
Biological Psychiatry (2022) Vol. 92, Iss. 12, pp. 952-963
Open Access | Times Cited: 11
Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model
Carolyn J. Stopera, Mitchell J. Bartlett, Chenxi Liu, et al.
Neuropharmacology (2024) Vol. 257, pp. 110047-110047
Open Access | Times Cited: 2
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Hugo Bottemanne, Lucie Berkovitch, Christophe Gauld, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 154, pp. 105410-105410
Open Access | Times Cited: 5
Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine
Zhen Zheng, Jillian L. Kyzer, Adam Worob, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 21, pp. 4113-4122
Open Access | Times Cited: 6
Identification of a novel norketamine precursor from seized powders: 2-(2-chlorophenyl)-2-nitrocyclohexanone
Yao‐Te Yen, Shih-Hao Tseng, Deng-Ying Huang, et al.
Forensic Science International (2022) Vol. 333, pp. 111241-111241
Closed Access | Times Cited: 4
Page 1

Scroll to top